肺外神经内分泌癌的当前治疗策略与未来方向:综述
肺外神经内分泌癌(EPNECs)因罕见而难以开展随机试验,治疗长期沿用SCLC方案。综述指出不同起源EPNECs在生物学上相似,PARP、Wee1、Aurora A激酶等靶点及免疫检查点抑制剂(ICIs)正在研究中;建议将EPNECs患者纳入不依赖原发部位的临床试验,并推动神经内分泌肿瘤board与部位特异性board协作。
要点
- EPNECs治疗长期沿用SCLC方案,但两者起源、临床病程和生存不同。
- 腺癌经系统治疗转分化使EPNECs增多,SCLC治疗格局变化可能影响EPNECs。
- PARP、Wee1、Aurora A激酶等靶点及ICIs在EPNECs中正在研究。
核心结论
- ICIs是数十年来SCLC系统治疗首个新选择,虽仅中等有效,在EPNECs中已显示一些有希望的结果。
- 为证明ICIs和其他新药对EPNECs的价值,患者应纳入不依赖原发部位的临床试验。
- 优化EPNECs临床决策需神经内分泌肿瘤board专家与部位特异性board成员协作,并将患者转诊至具备EPNEC专长的中心。
研究设计与样本
- 本文为综述,未报告系统检索范围、样本量或随机试验数据。
主要发现
- 不同起源EPNECs(原发恶性肿瘤或腺癌神经内分泌分化后)的肿瘤发生新信息显示其生物学相似。
- EPNECs发生相关的活化分子通路具潜在可靶向性,PARP、Wee1和Aurora A激酶等靶点正在研究中。
- ICIs已在SCLC中构成新治疗模式,并在EPNECs患者中产生一些有希望的结果。
临床怎么用
- EPNECs患者应纳入不依赖原发部位的临床试验,以验证ICIs和其他新药价值。
- 临床决策应由神经内分泌肿瘤board与部位特异性board协作制定。
- 患者应转诊至具备EPNEC专长的中心以优化临床决策。
局限性
- EPNECs罕见,阻碍随机临床试验开展,当前治疗证据多源自SCLC。
- 综述未报告系统检索范围及纳入研究的样本量或效应量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with extrapulmonary neuroendocrine carcinomas (EPNECs) receive essentially the same treatment as those with small cell lung cancer (SCLC) despite differences in origin, clinical course, and survival. This SCLC-based approach is attributable to the rarity of EPNECs, which impedes the use of randomized clinical trials. However, neuroendocrine carcinomas are becoming more common because of the increasing use of systemic cancer therapy for adenocarcinomas. This treatment can transdifferentiate certain adenocarcinomas into neuroendocrine carcinomas. In addition, the treatment landscape for SCLC is slowly changing, potentially impacting the treatment paradigms for EPNECs. OBSERVATIONS: New information on tumorigenesis of EPNECs from different origins, either as a primary malignant tumor or after neuroendocrine differentiation from adenocarcinomas, demonstrates their biological similarity. Activated molecular pathways that appear to underlie the development of EPNECs are potentially targetable, and some of these targets, such as poly(adenosine diphosphate-ribose) polymerase, Wee1, and Aurora A kinase, are currently under investigation. Immune checkpoint inhibitors (ICIs) already constituted a new treatment modality for patients with SCLC and produced some promising results in patients with EPNECs. CONCLUSIONS AND RELEVANCE: Although only moderately effective, the introduction of ICIs signifies the first new option in systemic treatment of SCLC in decades. To prove the value of ICIs and other new drugs for patients with EPNECs, these patients should be included in clinical trials independent of the primary tumor site. Furthermore, to optimize clinical decision-making for patients with EPNECs, experts from the neuroendocrine tumor board should collaborate with members from tumor site-specific boards, which will require patient referral to a center with EPNEC expertise.
引用
- Stelwagen J, de Vries EGE, Walenkamp AME, et al. Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas: A Review. JAMA Oncol. 2021. PMID: 33630040. doi:10.1001/jamaoncol.2020.8072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。